GKOS logo

Glaukos Corporation (GKOS)

$243.25

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GKOS

Market cap

$14.40B

EPS

-2.96

P/E ratio

--

Price to sales

15.95

Dividend yield

--

Beta

0.688044

Price on GKOS

Previous close

$244.88

Today's open

$242.60

Day's range

$239.65 - $247.12

52 week range

$87.32 - $255.19

Profile about GKOS

CEO

Thomas W. Burns

Employees

1094

Headquarters

Aliso Viejo, CA

Exchange

New York Stock Exchange

Shares outstanding

59196870

Issue type

Common Stock

GKOS industries and sectors

Healthcare

Medical Equipment & Supplies

News on GKOS

What Drove Glaukos Stock's 48% Rally Since the End of September?

Glaukos shares have surged 48.2% since September-end, fueled by strong Q3 results, raised sales guidance, Epioxa and iDose TR growth, and positive clinical data.

news source

Zacks Investment Research • 9 hours ago

news preview

NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump

NVIDIA's controversy and AI market correction prompt investors to explore healthcare, consumer staples and selective semiconductor opportunities.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:Stifel Healthcare Conference on Tuesday, November 10, 2026, at 8:40 a.m. ET in New York City, NYJefferies Global Healthcare Conference on Wednesday, November.

news source

Business Wire • Nov 3, 2026

news preview

Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK, Oct. 30, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday, November 4: S&P MidCap 400 constituent Okta Inc. (NASD: OKTA) will replace Kenvue Inc. (NYSE: KVUE) in the S&P 500, S&P SmallCap 600 constituent Glaukos Corp. (NYSE: GKOS) will replace Okta in the S&P MidCap 400, and McGrath RentCorp (NASD: MGRC) will replace Glaukos in the S&P SmallCap 600. S&P 500 constituent Kimberly-Clark (NASD: KMB) is acquiring Kenvue in a deal expected to be completed soon, pending final closing conditions.

news source

PRNewsWire • Oct 30, 2026

news preview

Glaukos Analysts Boost Their Forecasts Following Better-Than-Expected Q3 Earnings

Glaukos Corp (NYSE:GKOS) on Wednesday reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.

news source

Benzinga • Oct 29, 2026

news preview

Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction

Glaukos raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 target of $1 billion, after third-quarter sales jumped 58% to $211.0 million. Profit is thinner than the adjusted figures suggest.

news source

The Motley Fool • Oct 29, 2026

news preview

Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket

Shares of Glaukos Corp (NYSE:GKOS) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.

news source

Benzinga • Oct 29, 2026

news preview

Glaukos Q3 Earnings Call Highlights

Glaukos NYSE: GKOS reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment. The company raised its full-year 2026 revenue outlook and introduced a preliminary target of $1 billion in revenue for 2027.

news source

MarketBeat • Oct 28, 2026

news preview

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 29, 2026

news preview

Glaukos Announces Third Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include: Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis. U.S. Glaucoma record net sales of $118.6 mil.

news source

Business Wire • Oct 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Glaukos Corporation

Open an M1 investment account to buy and sell Glaukos Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GKOS on M1